Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study. - Mamakou V; Hackinger S; Zengini E; Tsompanaki E; Marouli E; Serafetinidis I; Prins B; Karabela A; Glezou E; Southam L; Rayner NW; Kuchenbaecker K; et al. (BMC psychiatry, 2018)